Benchmark analyst Mike Hickey reiterates Marcus (NYSE:MCS) with a Buy and maintains $20 price target.
Why Is Infection Treatment Focused-60 Degrees Pharmaceuticals Stock Soaring Today?
60 Degrees Pharmaceuticals Inc (NASDAQ: SXTP) announced the approval of an Investigational Review Board (IRB) sanctioned